Table 1. Characteristics of patients and controls enrolled in the study.
| Patient Characteristics | Control Characteristics | |||
|---|---|---|---|---|
| Whole cohort (23 patients) | Cohort suitable for HRV analysis (20 patients) | Whole cohort (24 controls) | Cohort suitable for HRV analysis (19 controls) | |
| Gender | ||||
| Female | 17 | 14 | 16 | 14 |
| Male | 6 | 6 | 8 | 5 |
| Age | ||||
| Mean age in the whole cohort | 47.5±11.4 | 49±11.4 | 45.3±10.6 | 47±10.6 |
| Mean age in males | 38.3±9.0 | 38.3±9.0 | 43.0±11.1 | 47.2±12.1 |
| Mean age in females | 50.7±10.5 | 53.6±9.2 | 47.4±9.9 | 47.5±10.6 |
| BMI | 23.4±4.2 | 23.7±4.4 | 23.8±3.1 | 23.8±3.3 |
| Angioedema type | ||||
| Type I | 20 | 17 | N/A | N/A |
| Type II | 3 | 3 | N/A | N/A |
| Prophylaxis | ||||
| None | 6 | 5 | N/A | N/A |
| Lanadelumab | 2 | 1 | N/A | N/A |
| Cinryze | 1 | 1 | N/A | N/A |
| Recombinant C1- inhibitor | 1 | 1 | N/A | N/A |
| Androgens | 13 | 12 | N/A | N/A |